Methotrexate (MTX) an antimetabolite of folic acid (FA), administered at low doses for long-term periods is one of the most efficacious treatment for a number of autoimmune diseases, including rheumatoid arthritis (RA). Toxicity, including nausea, vomiting, stomatitis, and cytopenias limit its clinical usefulness. The mechanism of toxicity is not known. Previous studies by this applicant, at this institution, indicate that FA supplementation (1 mg/day) ameliorates the toxicity of MTX in RA. We hypothesize that there is an optimal ratio of MTX to folate in the treatment of RA, which will allow toxicity to be minimized with no loss of efficacy. Further, the optimal ratio may be biochemically monitored. We propose to enroll ninety-three patients with Ra into a double-blind, placebo-controlled trial to evaluate the effect of 2 levels of FA supplementation in lessening toxicity while preserving efficacy. Simultaneous determinations of MTX and folate levels in plasma and peripheral blood mononuclear cells (PBMCs) and homocysteine levels in plasma, will be done to monitor the course of therapy. The precise mechanism of action of MTX in RA and other autoimmune diseases is not known. We hypothesize that it depends upon the inhibition of some but not all of the enzyme inhibitory activities of this drug. Using the MRL/1pr murine model of system lupus erythematosus, antifolates with narrower enzymatic inhibition patterns than MTX (eg selective inhibitors of the biosynthesis of thymidylate or purine nucleotides) will be tested. The MRL/1pr mouse model is an excellent model of autoimmune disease with manifestations including lymphoproliferation, glomerulonephritis, arthritis, vasculitic skin sores, and alopecia. Extent of hind limb pathology, abatement of proteinuria, severity of lymphoproliferation, reduction of vasculitic skin lesions, and survival will be markers of efficacy of the antifolate. Alterations in growth rate and early death will be markers of toxicity. Comparisons across antifolates should determine which folate-dependent pathways must be inhibited to produce efficacy with minimal toxicity. The animal studies will provide information to develop more selective drugs for use in human autoimmune disease. The protocol will be carried out at the University of Alabama at Birmingham, which as a Clinical Nutrition Research Unit, funded through the National Cancer Institute. These studies will be done in collaboration with faculty from the Division of Clinical Immunology and Rheumatology, which is the site of a Multipurpose Arthritis Center, and GCRC in the University Hospital.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000032-32
Application #
3089177
Study Section
General Clinical Research Centers Committee (CLR)
Project Start
1978-12-01
Project End
1992-11-30
Budget Start
1992-02-24
Budget End
1992-11-30
Support Year
32
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
McKenzie, Katelyn A; El Ters, Mirelle; Torres, Vicente E et al. (2018) Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol 19:378
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Morrison, Shannon A; Goss, Amy M; Azziz, Ricardo et al. (2017) Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome. Hum Reprod 32:185-192
Shen, Chengli; Landsittel, Douglas; Irazabal, María V et al. (2017) Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease. Am J Kidney Dis 69:482-484
Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247
Kline, Timothy L; Korfiatis, Panagiotis; Edwards, Marie E et al. (2017) Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int 92:1206-1216
James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4
Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628

Showing the most recent 10 out of 570 publications